ODYY - Odyssey Health to develop intranasal nerve agent antidote

• Odyssey Health ( OTCPK:ODYY ) said it launched a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.
• Nerve agents kill brain cells causing respiratory failure, seizures, and death within minutes of exposure, the company added.
• The breath-propelled intranasal device is lightweight. The drug-device combination is being developed to increase brain drug exposure in minutes, according to the company.
• Odyssey noted that oximes are an antidote for organophosphate nerve agents but the current use is through a skin auto-injector.
• Odyssey said that the novel Oxime-Intranasal combination include almost immediate exposure of the central nervous system, enhanced brain cell protection with less drug required given the targeted approach.

For further details see: